Soligenix is a late-stage biopharmaceutical company focused on rare diseases with unmet medical need. The company has no approved products and generates no commercial revenue, funding operations through government grants and equity issuances. Soligenix operates two segments: Specialized BioTherapeutics and Public Health Solutions. The lead asset is HyBryte (synthetic hypericin), a topical photodynamic therapy for cutaneous T-cell lymphoma (CTCL), a rare skin cancer affecting roughly 31,000 U.S. patients. HyBryte uses visible light rather than UV light to activate the compound and kill cancer cells, differentiating it from PUVA, the most common existing phototherapy. HyBryte completed a Phase 3 trial with statistically significant results, but the FDA required a second Phase 3 trial; a confirmatory study (FLASH2) began enrolling in December 2024, with top-line results expected in the second half of 2026. European approval is the nearer-term path. The pipeline also includes SGX302 (synthetic hypericin) for psoriasis in Phase 2a, and dusquetide-based candidates for Behçet's Disease and oral mucositis in head and neck cancer. The Public Health Solutions segment is entirely grant-funded and includes biodefense programs such as RiVax, a ricin toxin vaccine, and preclinical filovirus vaccines. Given its small headcount, Soligenix plans to partner for most commercialization, potentially self-commercializing only in orphan indications. Orphan drug designations for key assets provide meaningful post-approval exclusivity.